La Revue de medecine interne最新文献_第3页

[Time for assessing a clinical research project by one of 39 French ethic committees: A retrospective study between 2019 and 2023]. [法国 39 个伦理委员会之一对临床研究项目进行评估的时间：2019年至2023年的回顾性研究]。

La Revue de medecine interne Pub Date : 2024-08-14 DOI: 10.1016/j.revmed.2024.07.009

S Roriz, C Michel, M Mezzarobba, M Grit, G Baville Valade, E Cabrera, L ElotmanI, A Ambert, J-Y Lefrant, S Granier, N Boulet, Y Gricourt

{"title":"[Time for assessing a clinical research project by one of 39 French ethic committees: A retrospective study between 2019 and 2023].","authors":"S Roriz, C Michel, M Mezzarobba, M Grit, G Baville Valade, E Cabrera, L ElotmanI, A Ambert, J-Y Lefrant, S Granier, N Boulet, Y Gricourt","doi":"10.1016/j.revmed.2024.07.009","DOIUrl":"https://doi.org/10.1016/j.revmed.2024.07.009","url":null,"abstract":"Introduction: The study reported the time (from the initial submission to the final decision) to evaluate a clinical research project by one of the 39 French national ethics committees. The times from this final decision to the first participant inclusion and study achievement (first patient inclusion to the end of the last patient's follow-up) were also reported.Methods: Clinical research projects submitted between January 1st 2019 and June 30th 2023 were analyzed according to their type (research on drugs, clinical investigations, performance studies, research implying human person), and the promotor (industry, university hospital, general hospital, private medical institution, others). The times of assessment of the project by the ethic committee (from the initial submission to the final decision), of the first participant inclusion (from the approval of the project) and of study achievement (first patient inclusion to the end of the last patient's follow-up) were calculated.Results: Among 467 submitted clinical research projects, 424 were approved (90.8 %). The median time [Q1-Q3] to evaluate a project was 73 days [51-98] whatever the types of projects and promotors. In 307 accepted projects, the first patient inclusion occurred after 134 days [61-237] and was being waited for 347 days [306-510] in 39 other ones. In 122 projects, the time for study achievement was 446 days [230-731]. In 185 other projects, the inclusions were still in progress for 699 days [397-1098].Conclusion: In this concerned ethic committee, a final decision was edited after a median assessment time of 73 days (with >90 % approvals), shorter than the times to include the first patient and for achieving the study.","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Asymmetrical lower limbs]. [下肢不对称］

La Revue de medecine interne Pub Date : 2024-08-13 DOI: 10.1016/j.revmed.2024.08.001

Stéphane Vignes, Yasaman Jahromi, Cynthia Nabitz, Guillaume Canaud

引用次数: 0

[Serum hyperviscosity syndrome: Update 2024]. [血清粘稠度过高综合征：2024 年更新]。

La Revue de medecine interne Pub Date : 2024-08-07 DOI: 10.1016/j.revmed.2024.07.008

Pierre-Edouard Debureaux, Nathalie Parquet, Anne C Brignier, Dikelele Elessa, Virginie Lemiale, Virginie Siguret, Pierre-Antoine Quintard, Stéphanie Harel, Bruno Royer, Bertrand Arnulf, Alexis Talbot

引用次数: 0

[Aortitis]. [大动脉炎］

La Revue de medecine interne Pub Date : 2024-07-20 DOI: 10.1016/j.revmed.2024.06.015

Olivier Espitia, Claire Toquet, Bastien Jamet, Jean-Michel Serfaty, Christian Agard

{"title":"[Aortitis].","authors":"Olivier Espitia, Claire Toquet, Bastien Jamet, Jean-Michel Serfaty, Christian Agard","doi":"10.1016/j.revmed.2024.06.015","DOIUrl":"https://doi.org/10.1016/j.revmed.2024.06.015","url":null,"abstract":"Aortitis is a rare disease entity of unknown prevalence. Primary aortitis mainly affects the thoracic aorta. They are most often diagnosed on imaging by grade III 18-FDG uptake of the aortic wall on PET, or by circumferential thickening>2.2mm on CT or MRI with late-stage contrast. More rarely, aortitis is histologically proven, as in some cases of clinically isolated aortitis discovered after planned aortic aneurysm surgery or during aortic dissection surgery. The most common histological types are granulomatous/giant cell or lymphoplasmacytic. Clinical signs associated with aortitis are often non-specific: asthenia, fever, dry cough, chest, back, lumbar or abdominal pain. Aortitis can be divided into different etiological categories: primary aortitis, which includes vasculitis with a preferential or exclusive tropism for the aortic wall, aortitis secondary to systemic or iatrogenic diseases, and infectious aortitis. The main etiologies of primary aortitis are giant cell arteritis (GCA), Takayasu arteritis (TA) or clinically isolated aortitis. Aortitis secondary to systemic diseases is seen in atrophying polychondritis, systemic lupus and inflammatory rheumatic diseases such as spondyloarthropathy and rheumatoid arthritis. In both ACG and AT, aortitis is a negative factor, characterized by a higher risk of relapse, cardiovascular complications and increased mortality. The management of aortitis is insufficiently codified, and relies on the control of cardiovascular risk factors, with particular monitoring of blood pressure and LDL cholesterol, and on corticosteroid therapy and immunosuppressive drugs, the use of which will depend on the disease associated with the aortitis, the initial severity and comorbidities.","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Health literacy: Definition, assessment tools, state of the art in Europe, health consequences and ways to improve it]. [健康素养：定义、评估工具、欧洲的技术水平、对健康的影响以及改进方法]。

La Revue de medecine interne Pub Date : 2024-07-10 DOI: 10.1016/j.revmed.2024.06.014

Magali Le Brun, Dominique Godard, Lila Camps, Quentin Gomes de Pinho, Audrey Benyamine, Brigitte Granel

{"title":"[Health literacy: Definition, assessment tools, state of the art in Europe, health consequences and ways to improve it].","authors":"Magali Le Brun, Dominique Godard, Lila Camps, Quentin Gomes de Pinho, Audrey Benyamine, Brigitte Granel","doi":"10.1016/j.revmed.2024.06.014","DOIUrl":"https://doi.org/10.1016/j.revmed.2024.06.014","url":null,"abstract":"The term \"littératie\" is derived from the English word \"literacy\", which refers to knowledge and skills in the fields of reading, writing, speech (or other means of communication) and calculation that allow people to be efficient and integrated into society. Health literacy is a recent concept that relies on the ability to find, understand, evaluate and communicate information in ways that promote, maintain and improve the health of the individual in various settings over the course of life. The objectives of this review are first of all to realize an overview on the health literacy of populations in Europe. Then, we propose to study the link between health literacy and health status (risk behaviors, chronic diseases, morbi-mortality, adherence to care and medical monitoring) and to study its medico-economic impact. We also analyzed the association between personalized therapeutic education and health literacy. Finally, we propose a review of the means put in place in the care system to improve the health literacy of the patients we manage.","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141592470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The expert panel for Script Concordance Tests: A truly adequate reference?] [脚本一致性测试专家小组：真正充分的参考资料？］

La Revue de medecine interne Pub Date : 2024-07-09 DOI: 10.1016/j.revmed.2024.05.023

Luc Dauchet, Raphaël Bentegeac, Haress Ghauss, Marc Hazzan, Patrick Truffert, Philippe Amouyel, Victoria Gauthier, Aghilès Hamroun

引用次数: 0

Acute Q fever revealed by an anti-phospholipid syndrome: A case report. 由抗磷脂综合征引发的急性 Q 热：病例报告

La Revue de medecine interne Pub Date : 2024-07-01 Epub Date: 2024-05-17 DOI: 10.1016/j.revmed.2024.05.006

K Balasoupramanien, J-B Roseau, N Cazes, C Surcouf, E Le Dault

{"title":"Acute Q fever revealed by an anti-phospholipid syndrome: A case report.","authors":"K Balasoupramanien, J-B Roseau, N Cazes, C Surcouf, E Le Dault","doi":"10.1016/j.revmed.2024.05.006","DOIUrl":"10.1016/j.revmed.2024.05.006","url":null,"abstract":"Introduction: Q fever is a zoonosis caused by Coxiella burnetii. Acute infection is mainly asymptomatic. In other cases it mainly causes a flu-like illness, a pneumonia, or an hepatitis. We present an atypical case of an acute Q fever revealed by a massive pleural effusion.Case report: We report the case of a 43-year-old man referred to our hospital for an acute respiratory distress. Further analyses showed an exudative eosinophilic pleural effusion, associated with a pulmonary embolism and a deep femoral vein thrombosis. Aetiologic explorations revealed an acute Q fever (IgM and IgG against C. burnetii phase II antigens) associated with anti-phospholipids. The outcome was favorable with vitamin K antagonists, doxycycline, and hydroxychloroquine, till the negativation of the anti-phospholipid antibodies.Discussion and conclusion: During acute C. burnetii infections, anti-phospholipid antibodies are highly prevalent but thrombotic complications are rare. The 2023 ACR/EULAR APS criteria restricts the diagnosis of APS, as in our case of acute severe infection. In front of an atypical pneumonia and/or thrombotic events, screening of C. burnetii and anti-phospholipid antibodies could be useful. Given its low level of evidence, prolongated treatment by doxycycline, hydroxychloroquine ± anticoagulant for C. burnetii's associated anti-phospholipid syndrome is discussed, but succeeded in our case.","PeriodicalId":94122,"journal":{"name":"La Revue de medecine interne","volume":" ","pages":"444-446"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Portrait of Claire Le Jeunne, professor and former head of the internal medicine department at Hôpital Cochin, Paris]. [巴黎科钦医院内科教授和前主任克莱尔-勒让纳的肖像]。

La Revue de medecine interne Pub Date : 2024-05-01 DOI: 10.1016/j.revmed.2024.05.004

G. Martin de Frémont, K. Chevalier, A. Roeser

引用次数: 0

[Among patients with metabolic dysfunction associated steatohepatitis (MASH), is resmetirom 80 or 100mg superior to placebo in reversing MASH and/or fibrosis on liver biopsy, and is it safe?] [在代谢功能障碍相关性脂肪性肝炎（MASH）患者中，瑞美替罗 80 毫克或 100 毫克在逆转 MASH 和/或肝活检纤维化方面是否优于安慰剂？］

La Revue de medecine interne Pub Date : 2024-05-01 DOI: 10.1016/j.revmed.2024.05.007

L. Lanthier, D. Grbic, Marc-Émile Plourde, M. Cauchon

引用次数: 0

[Atypical alveolar echinococcosis with systemic involvement in a patient treated with dupilumab]. [一名接受杜匹单抗治疗的患者患上全身受累的非典型肺泡棘球蚴病]。

La Revue de medecine interne Pub Date : 2024-05-01 DOI: 10.1016/j.revmed.2024.04.002

L. Jacquel, B. Hoellinger, G. Marzolf, A. Stab, A. Guffroy

引用次数: 0